Nordic Nanovector has announced that the Japan Patent Office (JPO) has issued patent no. 5646652 entitled “Novel radioimmunoconjugates and uses thereof.”

The issued claims cover Nordic Nanovector’s proprietary radioimmunotherapy (RIT) technology, including the company`s lead product candidate Betalutin, a new targeted agent for the treatment of relapsed B-cell non-Hodgkin lymphoma (NHL).

"This patent provides additional intellectual property protection of our proprietary technology until 2031 and is an important addition to our patent portfolio,” said chief executive officer Luigi Costa. “By broadening patent coverage we are protecting commercial value for the investors in attractive markets such as Japan.”

Nordic Nanovector has earlier been granted patent protection in the two most important geographical markets for radioimmunotherapies, the USA and Europe.

Nordic Nanovector ASA, established in 2009, is a privately held company based in Oslo, Norway. The mission is to develop innovative radioimmunotherapeutics that target difficult to treat cancers using the company’s proprietary nanovector targeting technology.